Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

bioAffinity Technologies, Inc.

NASDAQ: BIAF · Industrial Applications and Services · 12 alerts · CIK 1712762

Share price
$2.00Close, Nov 16
Market cap
$3.64M
Shares outstanding
1.82MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Commercial Physical & Biological ResearchSIC 8731

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All bioAffinity Technologies, Inc. filings on SEC EDGAR ↗

8:04 AM ET 8-K
Business Update

bioAffinity Technologies Business Update

bioAffinity Technologies announced a record monthly testing volume for its CyPath Lung test in October 2026, with 235 tests performed. This volume represents a 29% increase over October 2025 and is equivalent to approximately 45% of the total tests performed in the entire third quarter of 2026. The company attributed the growth to expanded sales efforts and increased adoption by both new and existing physicians.

5:29 PM ET 8-K
Financial Results

bioAffinity Technologies Financial Results

bioAffinity Technologies reported its Q3 2026 financial results, highlighted by a 79% year-to-date increase in CyPath Lung testing revenue to $1.1 million. The company saw a 100% increase in test unit sales and an 89% increase in the number of ordering physicians compared to the prior year. Management noted continued momentum in commercialization and expansion of its government healthcare distribution network.

Term
Q3 2026

“Our third quarter results reflect the growing clinical adoption of CyPath® Lung as a vital tool for the early detection of lung cancer. With test unit sales doubling year-to-date and a significant increase in our physician base, we are seeing the direct impact of our commercial strategy and the clear need for noninvasive diagnostic solutions in the lung cancer care continuum.”

Maria Zannes, President and Chief Executive Officer
5:28 PM ET 10-Q
Financial Results

bioAffinity Technologies Q3 2026 Results: Net Loss of $5.28M, Loss Widens

For the nine months ended September 30, 2026, bioAffinity Technologies reported a net loss of $12.3 million on revenue of $3.9 million, compared to a net loss of $11.8 million on revenue of $4.6 million in the prior year period. The company's cash position decreased significantly to $2.6 million from $6.4 million at year-end 2025, driven by increased operating expenses in clinical development and general administration.

Key figure
Net loss $5.28M
8:31 AM ET 8-K
Business Update

bioAffinity Technologies Business Update

bioAffinity Technologies announced it will participate in the Lung Cancer Initiative of North Carolina’s 'Battle of the Blues' event on November 5, 2026. The company will highlight its CyPath Lung noninvasive diagnostic test alongside physicians and patient advocates to promote early lung cancer detection during National Lung Cancer Awareness Month.

9:30 AM ET 8-K
Clinical Trial Data

bioAffinity Technologies Clinical Trial Data

bioAffinity Technologies announced it will present positive research data at the CHEST 2026 annual meeting regarding its CyPath Lung test and a new investigational test for asthma and COPD-related lung inflammation. The presentation will focus on improving lung cancer risk stratification and managing pulmonary nodules using the company's noninvasive flow cytometry technology.

Counterparty
American College of Chest Physicians
9:23 AM ET 8-K
Clinical Trial Data

bioAffinity Technologies Clinical Trial Data

bioAffinity Technologies announced it will present positive research data at the CHEST 2026 annual meeting regarding its sputum-based tests for lung inflammation. The data demonstrates the ability to detect multiple protein biomarkers and biologic drug targets for asthma and COPD using the company's flow cytometry and AI platform. The research aims to support a precision medicine approach for identifying patients who could benefit from specific biologic therapies.

Counterparty
American College of Chest Physicians
4:31 PM ET 8-K
Capital Raise

bioAffinity Technologies Capital Raise of $4M

bioAffinity Technologies entered into a securities purchase agreement with an institutional investor to raise approximately $4 million in gross proceeds. The offering consists of 116,545 shares of common stock and pre-funded warrants for 536,836 shares, priced at $6.122 and $6.115 respectively, alongside a private placement of unregistered warrants.

Value
$4M
Counterparty
institutional investor
8:31 AM ET 8-K
Other 8-K Filing

bioAffinity Technologies Other 8-K Filing

bioAffinity Technologies received a Notice of Allowance from the Japan Patent Office for a patent covering its CyPath Lung test, a noninvasive diagnostic for early-stage lung cancer. This marks the company's first AI-algorithm-related patent in Japan and its fifth patent in the Asian market. The patent protects the company's proprietary method of using automated flow cytometry and machine learning to predict lung cancer likelihood.

Counterparty
Japan Patent Office
8:30 AM ET 8-K
Business Update

bioAffinity Technologies Business Update

bioAffinity Technologies reported that sales of its CyPath Lung test increased more than 100% through the third quarter of 2026 compared to 2025. The company delivered 1,620 tests through Q3 2026, driven by an 89% increase in the number of ordering physician offices and expanded utilization by existing customers.

8:31 AM ET 8-K
Business Update

bioAffinity Technologies Business Update

bioAffinity Technologies and its distribution partner AvMEDICAL debuted their joint exhibition of the CyPath Lung cancer test at the NAVREF 2026 Annual Conference. The update highlights progress under a previously announced distribution agreement aimed at expanding veteran access to noninvasive lung cancer testing through federal procurement channels.

Counterparty
AvMEDICAL
8:32 AM ET 8-K
Clinical Trial Data

bioAffinity Technologies Clinical Trial Data

bioAffinity Technologies is presenting clinical data and research updates for its CyPath Lung diagnostic at the 2026 NAVREF Annual Conference. The presentations include clinical case studies demonstrating how the test prevents unnecessary invasive procedures and an update on the 2,000-patient FlowPath Lung longitudinal study involving veterans and military personnel.

Counterparty
National Association of Veterans’ Research and Education Foundations (NAVREF)

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.